< Back to the supporters page ABOUT TERSERA TerSera Therapeutics LLC acquires and develops specialty pharmaceutical products with a focus on select therapeutic areas. Our focus is to bring intelligent solutions to prescribers and patients who need better solutions. We deliver a comprehensive set of programs that go beyond the therapy itself in order to provide improved outcomes for patients. Our products make a difference for patients and provide solutions for prescribers. Learn more at www.tersera.com . Talk to a NET nurse about carcinoid syndrome diarrhea. Go to www.enrollxermelo.com . This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Find compassionate support and resources for navigating a recent neuroendocrine cancer diagnosis. You're not alone in this journey. Navigating Your Recent Neuroendocrine Cancer Diagnosis PARA ESPAÑOL, HAGA CLIC AQUI You’ve just been told that you have Neuroendocrine Tumor, Neuroendocrine Cancer, or Carcinoid. You may be feeling panic, disbelief, despair or even a sense of relief to finally have a correct diagnosis. After those initial waves subside and you are thinking clearly again, the biggest question on your mind may be – “now what?” One important thing you can do is to take control by becoming your own advocate and leading your health team. Here is a beginner’s guide to NET that provides helpful facts and tips. SEVEN FACTS ABOUT NET 1. Neuroendocrine cancer is also known as neuroendocrine tumor, or NET. 2. Neuroendocrine Cancer is uncommon. Eight in 100,000 people are diagnosed per year in the United States. 3. Neuroendocrine Cancer can affect neuroendocrine cells throughout the body. 4. Neuroendocrine Cancer may be difficult to diagnose. 5. Some (but not all) Neuroendocrine Cancer patients have symptoms from their cancer. 6. The cause of Neuroendocrine Cancer is unknown. 7. Seeking the opinion of a specialist is important for all neuroendocrine cancer patients. 1. Neuroendocrine Cancer is also known as Neuroendocrine Tumor, or NET. It is pronounced NOOR-oh-EN-doh-krin TOO-mer and often abbreviated as NET. Hear the pronunciation . There are many terms or acronyms you may hear. Here are some of them: Neuroendocrine Neoplasm (NEN) is the official medical term often seen in medical literature such as the World Health Organization (WHO) classification of NEN. NEN includes both NET and Neuroendocrine Carcinoma (NEC). More aggressive Neuroendocrine Carcinoma (NEC) is treated differently than Neuroendocrine Tumors. Well-Differentiated and Low or Moderate Grade (G1/G2) NET tends to be slow growing, compared to High Grade (G3) NET or NEC which tends to be faster growing and Poorly Differentiated. Carcinoid is an old term meaning “cancer-like” that is falling out of favor because it is not accurate. NET is not cancer-like; it is cancer. Though some are localized (meaning it has not spread from where it originated from), many are malignant (meaning it has spread from where it originated from). You may still hear some physicians refer to NETs that originate from outside the pancreas such as the lung or small intestine as carcinoid tumors. Neuroendocrine Cancer is often used to refer to NENs (NET or NEC) by patient advocacy organizations as it spreads awareness to the fact that NET is a type of cancer and not benign as previously thought. Other terms you might hear refer to the primary tumor site (e.g., PNET or pancreatic NET) or the hormone that the tumor secretes (e.g., Insulinoma or VIPoma). 2. NET is a rare cancer. About 8 in 100,000 people are diagnosed annually in the United States. NET is considered rare by incidence, the number of patients diagnosed per year in the U.S. The prevalence of patients living with NET exceeds those living with stomach and pancreatic adenocarcinoma combined. Both the incidence and prevalence of NET are on the rise. 3. NET can affect neuroendocrine cells throughout the body. These are hormone-producing cells, most commonly found in the gastrointestinal system (stomach, small intestine, large intestine, rectum), the lung, pancreas or other parts of the body. NET often spreads (or metastasizes) from the primary site of origin to the lymph nodes, liver and bones. The tumors that have spread are called metastases. A Note About Prognosis: A common question we hear is, “How long do I have to live?” It is common for patients to report that their doctor told them that they had only months to live with the recommendation to “get their affairs in order.” In contrast, NET specialists will often say, “We don’t know how long you have.” The more you learn about NET, the more you will learn that prognosis is difficult to predict. NET is unpredictable, and each person’s case is unique, so it is typically difficult to predict a prognosis. Also, many of the statistics you might read are outdated. There have been many recent advances in NET research, which have led to earlier detection and more treatment options. As a result, patients are living longer with the disease. There are many in the NET community living with this disease for over a decade. 4. NET is a cancer that is difficult to diagnose. This is because not everyone with NET is symptomatic. For those who do have symptoms (less than half of all NET patients), these symptoms are vague and include flushing, diarrhea, nausea, abdominal cramping, bloating/gas and shortness of breath. 5. Some (but not all) NET patients have symptoms from their cancer. Typically, only those patients who have hormone-producing tumors called functional tumors have symptoms. For example, about 20-30% of people with small bowel (NETs) develop Carcinoid Syndrome (CS) with tumors produce serotonin. 6. The cause is unknown. People often wonder if they might have done something to cause their cancer. The answer is NO. Although there are a few types of NET that have a genetic correlation, most have no known cause. 7. Seeking the opinion of a NET specialist is important for NET patients. When most people are first diagnosed with neuroendocrine cancer, it is usually not by a NET specialist. Most patients end up seeking a second opinion with a NET expert, which may mean traveling outside of the area in which they live. Because NET is a rare disease, many doctors know little about it or the recent advances in diagnosis and treatment. A NET specialist can help guide your treatment plan. They can collaborate with your multidisciplinary doctors to manage your symptoms, monitor your disease and recommend treatments best suited for you. According to a large-scale survey of NET patients , those who received their care at a NET specialty center felt significantly more satisfied with their medical treatment and more knowledgeable than those who did not visit a NET specialty center. 1. Get organized NET VITALS is an ideal place to start. NET VITALS is a downloadable document to collect and keep the essential information about your specific NET disease. This comprehensive, curated list, contains what you and your healthcare professionals need to know about your neuroendocrine cancer. NET VITALS is a patient-physician communication tool, a “passport,” containing all the vital NET information in one location and simple to bring to your medical appointments. While it is not a medical document, it has been reviewed by NET specialists who agree that completing NET VITALS, as much as possible before their appointment, is helpful. Please note: NET VITALS is intended for informational and educational purposes only. LACNETS does not collect or store your information. It is for your personal use only. NET VITALS Helps: Educate you on what information is crucial to know about your NET disease. You organize, collect and compile this information into one comprehensive document that is easy to share with all healthcare professionals. Prepare you to ask relevant questions of your NET specialist for an optimal visit. Record Keeping Tips: Many people choose a way to organize their information such as a three-ring notebook or file folder. If you keep paper copies of labs, imaging reports, and pathology reports, consider scanning them so you have a digital copy as well. This not only makes your records easier to access, it also ensures that you do not lose your only paper copy! Download the Abridge app to record your healthcare visits and get transcriptions you can reveiw. To obtain second opinions, choosing an electronic system of record keeping on your computer or a cloud service can be helpful if you want to send information electronically. Some people track lab results on a spreadsheet to follow trends. Whatever method you choose, organization is key! You want to know where everything is stored. Information should be easy for you to access and share with your medical team when needed. NET VITALS is an ideal place to keep your vital NET information. After every scan, go to medical records or the film library and ask for a CD of the scan images for your records. We recommend requesting two copies, one for your NET specialist and one for second opinions or other members of your medical team. Never give away your only copy of any CD, report or document. After any biopsy or surgery, ask your doctor for the pathology report. These are often unavailable in your online patient portal, so you may need to request a copy. After any surgery or procedure, ask for the operative report or procedure report. These are often unavailable in your online patient portal, so you may need to request a copy. 2. Educate yourself on the disease: Learn to speak "NET" Watch this short (~5min) “What is NET?”video . It is great to share with family & friends to help them learn and understand more about your cancer. Watch this helpful introduction to NETs presentation by NET expert Dr. Pamela Kunz, as well as the “NETs 101” presentation by Dr. Sandy D. Kotiah, Medical Oncologist at Mercy Medical. This informative presentation, “What to Expect with a NET Expert Consultation” by Dr. Heloisa Soares at Huntsman Cancer Institute. The LACNETS webinar, “Sequencing of Neuroendocrine Tumor Treatments” with Dr. Eric Liu, General Surgeon & Neuroendocrine Specialist at Rocky Mountain Cancer Center. Check out Triage Cancer’s valuable organization resources: “Checklist: Getting Organized.” “Checklist to Avoid Financial Toxicity ” Cancer Rights Guide: “Navigating Employment, Insurance, & Finances” The National Comprehensive Cancer Network (NCCN) is an alliance of the leading cancer centers across the country that develop and publish up-to-date, evidence-based practice guidelines called NCCN Guidelines . Because these NET guidelines are recognized as the standard in cancer care, it is an essential resource in discussions with your medical team. It is also an excellent reference when dealing with insurance claims. Order your free Neuroendocrine Cancer Guide for patients and families from Neuroendocrine Tumor Research Foundation (NETRF). Download or request The Healing NET Foundation Navigating the NET Patient Journey peer-to-peer publication for patients and caregivers. Canadian Neuroendocrine Tumor Society (CNETS) has a downloadable Reference Guide for Patients and Families. The Global NET Patient Information Pack by the International Neuroendocrine Cancer Alliance (INCA) is available for download in 10 languages. Connect with and learn from others who are living with or have been affected by NET. Register for our Weekly Virtual Support Group every Wednesday from 12-1:30 PM Pacific Time. Subscribe to the LACNETS YouTube channel to find over 275 videos on various topics. 3. Find Support Support groups are often a rich source of educational meeting and resources for patients and their families. People often learn much from the experiences of others. Some report finding their NET specialist(s) because of attending a support group. Join our support community . We often hear people say, "I thought I was the only one with the disease." Connecting with others can help you feel less alone. Connect with a mentor. NETCONNECT connects you with another NET patient or caregiver for questions, support and more. 4. Find a NET Specialist Studies show that NET patients who are seen by a multidisciplinary team tend to have better outcomes. Typically, NET centers are able to diagnose and treat NET faster and more accurately. It is best to have a multidisciplinary approach where a team of NET specialists with different areas of expertise get together and review your case. This often takes place at a tumor board where your case is discussed and reviewed by several doctors including medical oncologists, endocrinologists, gastroenterologists, surgeons, radiologists, nuclear medicine doctors, and pathologists. Since patients are not allowed to be present, this video of a mock tumor board at a LACNETS conference gives you an idea of what one is like. How to Find a NET Specialist: Neuroendocrine Tumor Research Foundation (NETRF) is a good place to start. Many of the NET specialists (including oncologists, surgeons, endocrinologists, etc.) have been speakers at past NET patient conferences and meetings. Find and watch NET experts from our Video Library . You may find it helpful to “see” the doctor before your appointment. 5. Decide who will be your quarterback Patients often see many doctors with different areas of expertise. Some patients seek opinions from multiple NET experts as well. The important thing is finding a physician who you feel listens to and addresses your concerns, explains things in a way you understand, and provides access to the treatments you need. A collaborative relationship is important, both with you and the rest of your team. Once you have selected your multidisciplinary medical team, decide who will lead and call the shots. 6. Attend a NET patient education conference Learn about upcoming virtual and in-person conferences hosted by LACNETS and the broader NET Community. It is worthwhile to stay connected and interact with NET experts, patients, caregivers and those who serve the NET Community. Click here to read "Why Attend NET Patient Education Conference" 7. Breathe And last but not least, don’t forget to breathe. Stop to reflect and remember the reason we educate ourselves is to LIVE better. For most of us, living with NET is more like running a marathon than a sprint. Some feel a pressure to spend every waking minute learning about the disease so they don’t miss something that could mean the difference between life or death. For the majority of NET patients, that is simply not reality. It is just as important to take care of our emotional, mental and spiritual health as it is our physical health. If you’re feeling overwhelmed, it’s a good idea to take a break and do something that is life-giving and unrelated to cancer. Find the presence of mind to enjoy life’s simple pleasures like a walk on the beach, being in nature, gardening, seeing a movie, going to a museum or attending a concert. When you feel rested and ready to resume your education, come back to learn more about NET. It’s amazing how restorative taking just one minute to breathe can be. Click here to read "Breathe" blog post SEVEN TIPS FOR THE NEWLY-DIAGNOSED PATIENT 1. Get organized 2. Educate yourself on the disease: Learn to speak "NET" 3. Find support 4. Find a NET specialist 5. Decide who will be your quarterback 6. Attend a NET patient education conference 7. Breathe

Learn more about the NET experts presenting on various topics during the 2024 LACNETS Neuroendocrine Tumor Patient Conference. 2024 LACNETS Conference Speakers Understanding NET Diagnosis: The Work-Up & What You Need to Know About Your NETs Chandrikha Chandrasekharan, MBBS Medical Oncologist, University of Iowa Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at University of Iowa. She did her initial medical training in India at Kilpauk Medical College. She moved to the USA to complete her internal medicine residency at University of Florida College of Medicine at Jacksonville. Dr. Chandrasekharan is board certified in Medical Oncology and Palliative Medicine. After completing medical oncology fellowship at LSU Shreveport, she pursued an additional year of advanced oncology training in gastrointestinal malignancies at Mayo Clinic. Dr. Chandrasekharan's clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. Understanding NET Scans Nadine Mallak, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, M.D. is a double boarded Associate Professor of Diagnostic Radiology at OHSU, in the divisions of Body Imaging, and Molecular Imaging & Therapy. She received her M.D. degree from Saint Joseph University Medical School in Beirut, Lebanon, followed by a Diagnostic Radiology residency at Hotel Dieu de France, Beirut. Subsequently, she finished fellowships in Neuroradiology and Abdominal Imaging, and a residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics. Dr. Mallak is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for prostate cancer, neuroendocrine tumors and pheochromocytoma/paraganglioma. In addition to her research projects, she’s passionate about education. She was voted by the radiology residents "outstanding teacher of the year" for the year 2019-2020, and by the graduating senior residents “outstanding board reviewer” for the year 2021-2022 In her free time, she enjoys painting, mostly with acrylic and watercolors, reading, hiking, and exploring the gorgeous nature in the Pacific Northwest. Understanding Surgery for Liver NETs Callisia Clarke, MD Surgical Oncologist, Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Understanding Carcinoid Crisis Julie Hallet, MD, MSc., FRCSC Surgical Oncologist, Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. Understanding Liver-Directed Therapy Michael Soulen, MD FSIR FCIRSE Interventional Radiologist, University of Pennsylvania Michael C. Soulen, MD FSIR FCIRSE is the Professor of Radiology and Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center and Director of Clinical Research in the Division of Interventional Radiology. His major clinical and research focus for the past 30 years has been image-guided cancer therapy (interventional oncology), with a specific focus on embolotherapy and ablative therapy of solid tumors in the liver and kidney. Animal research includes swine, rabbit, and rat models for liver-directed therapies, investigating novel embolic agents, novel ablation devices, and ultrasound-mediated drug delivery using novel drug-loaded microbubble contrast agents. Clinic trials focus on embolotherapies for primary liver cancers, liver metastases from colorectal and neuroendocrine tumors, and renal cell carcinomas. Current clinical investigations focus on synergy between locoregional and systemic therapies, including 1) pharmacologic modulation of the metabolic stress response under conditions of embolic ischemia; 2) IR therapies as immunostimulants combined with immune checkpoint inhibition, 3) radioembolization with radiosensitizing drugs; 4) serial biopsy for tumor cell culture, rapid drug screening, sequencing and testing in PDX mice, with the goal of personalized precision medicine; and 5) the first international randomized trial comparing embolotherapy techniques for neuroendocrine tumor liver metastases. Dr. Soulen received Research Mentor awards from the University of Pennsylvania Department of Radiology and the North American Neuroendocrine Tumor Society and the Gold Medal from the Society of Interventional Radiology. Understanding PRRT Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). Understanding the Latest in Systemic Treatments & Considerations for Treatment Sequencing Thorvardur Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson currently serves as President for the North American Neuroendocrine Tumor Society (NANETS). NET Tumor Board Panel: Understanding NET Liver Metastases Jaydira Del Rivero, MD Endocrinologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training through the MSTP (joint MD/PhD) program at Stony Brook University in New York in 2005. His master’s degree was in Anatomical Sciences, and his PhD in Biomedical Engineering. He subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty in Radiology at Stanford for 8 years, until moving to OHSU in 2018. Dr. Mittra is interested in all aspects of Nuclear Medicine imaging, therapy, and research. This includes adult and pediatric general nuclear medicine imaging with gamma camera and SPECT, PET imaging for oncology, cardiac, and neurologic applications, as well as bone densitometry (DXA imaging). Targeted Radioisotope Therapies (TRT) are of particular interest; including various applications in oncology and he is a nationally-recognized expert in this area. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is the current Medical Director of the Healing NET Foundation (HNF). Osman Ahmed, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. Gangandeep Singh, MD Surgical Oncologist, City of Hope Dr. Singh is an internationally recognized liver and pancreas surgeon. He is the Chief of Surgical Oncology program, Head of the Hepatobiliary & Pancreatic Surgery Program and the Director of the Neuroendocrine Tumor Program at City of Hope Comprehensive Cancer Center (Phoenix). Dr. Singh is a seasoned leader with more than 20 years of experience building and leading several surgical teams to world-wide recognition. Dr. Singh began his faculty academic career at the Keck School of Medicine at University of Southern California (USC) in Los Angeles. From there, he was appointed as the Director of the Liver and Pancreas Center at the John Wayne Cancer Institute, Santa Monica, CA, where he also served as Chair of the Cancer Committee, and Vice President for Fellowship Education. In 2010, City of Hope (Duarte) recruited Dr. Singh to spearhead the liver and pancreatic cancer program. He was appointed Professor of Clinical Surgery and as the new Chief of the Division of Surgical Oncology (2011-2019) and hoisted their program to national recognition. He has an extensive referral base that reflects peer recognition of his clinical acumen and surgical expertise and is listed in “America’s Top Surgeons”, “Best Doctors of America”, “Super Doctors” and “Top Doctors of America.” Prior to his tenure in the Unites States, he earned is his Medical Degree from the Mahatma Gandhi Institute of Medical Sciences, India, and then trained at some of the finest cancer centers across the globe. These institutions include Tata Memorial Hospital and Cancer Center (Bombay, India), René Descartes University (Paris, France), and the Royal Liverpool University Hospital (Great Britain- England). In the USA, these institutes include the Marion Bessin Liver Center at the Albert Einstein College of Medicine (New York), Maricopa Medical Center (Phoenix), and the University of Iowa Hospitals & Clinics (Iowa City). Dr. Singh is a board-certified surgeon, a Diplomate of the American Board of Surgery and a Fellow of the American College of Surgeons. He is a member of some of the top elite surgical societies and has served as invited speaker/chair at several national and international conferences. He was a panel member of the National Comprehensive Cancer Network (NCCN) for Hepatobiliary Cancers for the last 10 years, that lays down the guidelines for the standard of care for these cancers; providing direction to both patients and physicians across the USA and the rest of the world. Dr. Singh has a very thoughtful, effective, and yet forceful approach to beating cancer, in a systematic fashion working with an outstanding multi-disciplinary team. Dynamic and compassionate, he is a skilled and an accomplished surgeon. He has extensive experience in liver and pancreatic diseases and other gastrointestinal cancers. His work is very well published with numerous publications in prestigious journals. His publications encompass complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions following difficult pancreatic surgery for pancreatic cancer, and advanced robotic surgery. His work in robotic surgery has been presented on the national podium at the Society of Surgical Oncology (SSO), Americas Hepato-Pancreato-Biliary Association (AHPBA), Society of Laparoscopic & Robotic Surgeons (SLRS) and other national meetings. An innovator at heart, Dr. Singh is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborative endeavors with engineers from California Institute of Technology (Caltech) & Harvey Mudd College. He has several invention disclosures and patents. In addition to a large clinical practice, Dr. Singh is passionately advancing cutting-edge translational research. He collaborates with City of Hope’s molecular biologists, X-ray crystallographers, structural chemists, and super-resolution scientists. A leader who is passionate about empowering teams and individuals to achieve their full potential, Dr. Singh has been recognized with several awards and leadership positions. Understanding NET Guidelines Jaydira Del Rivero, MD Endocronologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Understanding the Latest NET Clinical Trials Pamela Kunz, MD Medical Oncologist, Yale Medicine Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. She was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021, she was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity. MODERATORS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. MARY DONLEVY LACNETS Board member and NET Patient Advocate Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. Beth DeBlase NET Patient Beth was diagnosed in 2016 with metastatic, midgut NET. In that time, she has made aesthetic oncology and integrative therapies her passion. Her mission is to help enhance the quality of life for fellow cancer patients and caregivers, including herself, her four children, and husband. << Go back to the 2024 Annual Conference Page

< Back to the supporters page Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Introducción NETs - La Presentación NETs de Elevador DescargarLa Tarjeta NET Intro La tarjeta NET Intro se puede completar digital o físicamente. (NOTA: Todos los recursos marcados con * están disponibles únicamente en Inglés) ¿QUÉ ES LA PRESENTACIÓN NETS DE ELEVADOR? La “Presentación NETs de Elevador” es una forma de presentarte. La razón por la que se llama de “Elevador" es porque debe ser lo suficientemente breve para poder decirla durante un viaje en elevador. Definimos una “Presentación NETs de Elevador” como una sinopsis de dos oraciones de tus NETs, que puedes comunicar en 30 segundos o menos. Si estuvieras en un elevador con un experto en NETs y solo tuvieras 30 segundos, la “Presentación NETs de Elevador” sería la introducción ideal, es concisa e ilustra claramente las características más importantes que se necesitan saber sobre tu condición. Esta es tu Introducción NETs, la mejor forma de presentar rápidamente el historial de tus NETs. La “Presentación NETs de Elevador” consta de dos oraciones y contiene la información descrita en las secciones 2 a 6, de la página 1 de NET VITALS. ORACIÓN #1: 1. Tu relación con NETs: Si vives con NETs, puedes comenzar la oración con: “Estoy viviendo con…”. “Me diagnosticaron…”. Si eres cuidador o ser querido de alguien que vive con NETs, puedes comenzar la oración con: “Mi cónyuge/hijo/padre/pariente/amigo/otro pariente vive con…”. “Mi cónyuge/hijo/padre/pariente/amigo/otro pariente fue diagnosticado con…”. Nota: Porque creemos que las palabras tienen poder, no aconsejamos identificarte como paciente o decir que estas enfermo. En su lugar, alentamos el uso de "Estoy viviendo con" o "Me diagnosticaron" o "Me diagnosticaron tal año con..." o incluso "Tengo...". Algunas personas incluso dicen "Estoy viviendo bien con..." porque da el mensaje de que las personas con NETs pueden tener una vida plena. 2. Diferenciación tumoral: Esto es "bien diferenciado" o "poco diferenciado". Se refiere a qué tan anormales se ven las células bajo el microscopio, en comparación con las células sanas circundantes 3. Grado del tumor: Puede ser grado 1, 2 o 3. El grado se refiere a la rapidez con la que se dividen las células tumorales. Si conoces tu ki-67 puedes agregarlo, ya que determina el grado del tumor. El ki-67 lo puedes encontrar en el reporte de patología, estos reportes se realizan cada vez que se extrae tejido de tu cuerpo, generalmente por medio de una biopsia o una cirugía. Es importante aclarar que el grado es diferente a la etapa o estadio, estas ultimas se refieren a qué tanto se ha desplazado el cáncer desde el sitio original del tumor. Es fácil confundir grado con etapa, pero en realidad dicen cosas muy diferentes. El público en general está familiarizado con la estatificación, porque es una forma común de describir un cáncer y da una idea de la prognosis de una persona. Sin embargo, es importante recordar que con el Cáncer Neuroendocrino, la etapa 4 no significa lo mismo que la etapa 4 de otros tipos de cáncer. Tenga en cuenta que los NETs pulmonares no están clasificados por grado, se clasifican en: Carcinoma Típico, Carcinoma Atípico, Carcinoma Neuroendocrino de Células Grandes y Carcinoma de Células Pequeñas. Los Feocromocitomas y los Paragangliomas tampoco se clasifican por grado. Vea esta infografía detallada* del podcast NETWise de NETRF sobre los NETs de pulmón Nuestros recursos de NETs de Pulmón se pueden encontrar aquí* NETWise Infographic Stage, Differentiation & Grade, courtesy of Neuroendocrine Tumor Research Foundation - Download Here 4. Estado funcional del tumor: Puede ser funcional o no funcional. Esto significa específicamente si los tumores producen hormonas (funcionales) o no producen hormonas (no funcionales) y no es indicación de la presencia de síntomas, ya que los síntomas pueden ser producidos por una variedad de razones. 5. Sitio de origen del tumor y metástasis: El sitio de origen es donde se origina el Tumor Primario y es el que define el tipo de NETs (NETs Pancreáticos (pNETs), NETs de Intestino Delgado, NETs de Pulmón, NETs de Colon, etc.) Metástasis es cualquier otro lugar (órgano diferente al Sitio Primario) en donde se encuentren mas tumores del mismo tipo que el Tumor Primario (por ejemplo en el hígado, los huesos, etc.) El sitio de origen será siempre el mismo, aún después de haber extirpado el tumor primario e incluso al no tener ya evidencia de la condición. Una de las razones por las que identificar el sitio de origen (Tumor Primario) es importante, es que le permite a tu equipo médico determinar y evaluar las opciones de tratamiento disponibles y aplicar las más adecuadas para cada caso. 6. Año en el que recibiste el diagnóstico. Este es opcional. ORACIÓN #2: La oración #1 es la base principal. Una vez que hayas dominado la oración #1, entonces (y solo entonces) estarás listo para agregar la oración #2. A la mayoría de nosotros nos resulta más fácil la oración #2 porque estamos familiarizados con los tratamientos y los procedimientos hemos recibido. La oración #2 consiste en eso, es un resumen breve de tus cirugías y tratamientos. La clave aquí es ser conciso. Estos son ejemplos de la oración #2: “A mi esposo lo operaron y le están dando un análogo de somatostatina (lanreotida u octreotida), terapia dirigida al hígado y PRRT” “Me hicieron una resección intestinal en Diciembre del 2022 y me están dando inyecciones Lanreotida, 120mg cada 28 días” ¡Ahí está! Tu historial en una breve Introducción NETs de dos oraciones, en 30 segundos o menos. Si bien puede parecer simple, sabemos que construir tu “Presentación NETs de Elevador” puede presentar ciertos retos. Además, se necesita algo de trabajo y práctica para poder pronunciar tu “Presentación NETs de Elevador” cómodamente. ¡Escríbela, tenla a mano y practica, practica, practica ! Mientras mas lo repitas, más cómodo te sentirás al decirlo y, en poco tiempo, lo podrás decir de una manera muy natural. ¿CUÁLES SON LOS BENEFICIOS DE APRENDER LA “PRESENTACIÓN NETS DE ELEVADOR”? Al aprender a "hablar NET" estarás en la misma página que un experto en NETs. Al decir tu “Presentación NETs de Elevador”, estás comunicando los elementos críticos que los expertos o tu equipo médico necesitan saber para tomar decisiones de tratamiento. Es importante que CONOZCAS Y COMPRENDAS TU CONDICIÓN y no dependas únicamente de tu equipo médico para eso. Aprender a hablar NET te ayuda a saber qué información o tratamientos son relevantes para tu caso. Al participar en reuniones educativas, podrás interpretar y entender mejor la información. Al buscar ensayos clínicos * , es posible que te ayude a determinar cuales son los mas apropiados para ti. Podrás comunicar los elementos esenciales de tus NETs de manera concisa, clara y eficiente. Comunicar los elementos críticos de la condición de una manera eficaz, nos permite tener una mejor utilización del tiempo y esto nos da una mejor oportunidad de hablar sobre tratamientos o de obtener respuestas a nuestras preguntas. Ya sea en un grupo de apoyo, con otras personas viviendo con NETs, con tu equipo médico o al conocer a un experto en NETs en una conferencia, la “Presentación NETs de Elevador” te ayudara a comunicar clara y eficazmente toda la información importante de tu condición, contenida también en tus NET VITALS*. ¿QUÉ NO DEBE ESTAR EN TU NET INTRO? Las palabras tienen poder. Desalentamos el uso de las palabras “Paciente” o “Enfermo” al referirnos a nuestra persona o a nuestros seres queridos. Preferimos el uso de palabras que empoderen y que muestren que nos vemos como personas completas y que no somos definidos por una enfermedad. Ten en cuenta que tu “Presentación NETs de Elevador’ no es lo mismo que tu historia. Hay momento y lugar para contar la historia de tu diagnóstico y de el impacto personal que ha causado. La “Presentación NETs de Elevador” no reemplaza tu historia, es una habilidad diferente, con un propósito diferente. ¡El conocimiento es poder! En esta montaña rusa, donde a veces podemos sentir que todo esta fuera de control, esto es algo que podemos controlar. Aprender tu “Presentación NETs de Elevador” te ayuda a comunicarte en el idioma de los expertos de NETs. Al cerrar las brechas de conocimiento y comprender los términos y conceptos fundamentales de NET, podemos ser mejores pacientes, cuidadores, promotores o defensores. ¡¡Crea tu “Presentación NETs de Elevador” y aprendamos juntos a hablar NET!! DescargarLa Tarjeta NET Intro La tarjeta NET Intro se puede completar digital o físicamente. *Original site translated by Michel DeQuevedo from NETs Mexico . Recursos Si no está seguro de lo qué significan los términos anteriores o de cómo encontrar la diferenciación, el grado o el ki-67 en su informe patológico, le recomendamos los siguientes recursos: Infografía NETWise de NETRF "Etapa, diferenciación y grado"* Episodio 1 del podcast NETWise de NETRF: Lo que tienes que saber sobre los NETs * Seminario web: NET VITALS (a partir de 14:20 minutos) * Seminario web de patología * a cargo de la Dra. Sue Chang (a partir de las 36:43) Video: Manejo de Síntomas * por la Dra. Del Rivero (habla de tumores funcionales y manejo del síndrome carcinoide) NOTA: NET Intro es un documento solo para uso personal. LACNETS no lo envía ni lo recopila. Es un documento que debe completar y llevar a su cita con el médico. Este documento está destinado únicamente a fines informativos y educativos y no reemplaza el asesoramiento médico profesional. Siempre consulte con su médico o proveedor de atención médica.

Join NCF for Arizona. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/playlist?feature=share&list=PLPAgUIq-85n87MCeOUD77oRr6XQYk-mrG ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. Hear presentations from 8 NET experts. Listen to patient stories. Learn about the latest in surgery, liver-directed therapy, systemic therapy, PRRT, and clinical trials. Ask questions during the extended live question and answer session. Find out how you can spread awareness about neuroendocrine cancer. Network with other patients and caregivers in the post-event reception. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Junaid Arshad, University of Arizona Cancer Center (UACC). This event will not be broadcast. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 1:30 - 2 PM Check-in 2 - 2:10 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 2:10 - 2:15 PM Patient Story Kimberly, NET Patient 2:15 - 2:30 PM NETs 101: NET Terms & Concepts You Need to Know Bassam Sonbol, MD, Medical Oncologist, Mayo Clinic Phoenix 2:30 - 2:45 PM Surgery for NETs: To Cut or Not to Cut? Gagandeep Singh, MD, Surgical Oncologist, City of Hope Phoenix 2:45 - 3 PM Liver-Directed Therapy: Killing Liver Tumors Without a Big Scar Gregory Woodhead, MD, PhD, Interventional Radiologist, University of Arizona Cancer Center 3 - 3:15 PM Systemic Therapy for NETs: Treatment Options for Metastatic Tumors Heloisa Soares, MD, PhD, Medical Oncologist, Huntsman Cancer Institute 3:15 - 3:30 PM PRRT: Current & New Trends Holly Thompson, MD, MPH, Nuclear Medicine, University of Arizona Cancer Center 3:30 - 3:45 PM Break 3:45 - 3:50 PM Nursing Perspective on the Management of NETs Linda Moe, RN, University of Arizona Cancer Center 3:50 - 4:05 PM Clinical Trials: The Latest & Greatest Pamela Kunz, MD, Medical Oncologist, Yale Cancer Center 4:05 - 5 PM Q&A with Expert Panel All Faculty - Moderated by Dr. Junaid Arshad, Medical Oncologist, University of Arizona Cancer Center & Lisa Yen, LACNETS 5 - 6 PM Networking Reception ABOUT OUR SPEAKERS Dr. Junaid Arshad Medical Oncologist, University of Arizona Cancer Center (UACC) Host/Moderator/Speaker Dr. Junaid Arshad is an Assistant Professor of Medicine and our new faculty member of GI Medical Oncology. He received his medical degree from King Edward Medical University, Lahore, Pakistan. He completed his Internal Medicine Residency at St. Mary's Hospital, Waterbury, CT. He has joined the Cancer Center after his Hematology and Medical Oncology Fellowship from University of Miami, FL. Dr. Arshad is a Clinical and Translational Scientist with a focus on developing novel therapeutics for several areas of Upper GI Oncology. Dr. Arshad's Clinical and Research focus targets mainly the Upper GI Oncology including Gastrointestinal Stromal Tumors, Gastric Cancers, Esophageal Cancers and Neuroendocrine Tumors. He is a part of several clinical trials and has contributed to several peer reviewed publications. His prior research focuses on the use of biomarkers such as circulating tumor DNA (ctDNA) in the diagnosis, treatment and surveillance of Gastrointestinal Stromal Tumors. He has expanded his areas of research interest to include other disease modalities such as Neuroendocrine Cancers. Dr. Pamela Kunz Medical Oncologist, Yale Cancer Center Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including past President of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. Dr. Kunz was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021. Dr. Kunz was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity and received the 2024 'Distinguished Mentor Award' by the North American Neuroendocrine Tumor Society. X @PamelaKunzMD Linda Moe, RN Registered Nurse, University of Arizona Cancer Center (UACC) I have been an oncology nurse for 34 years, working in both inpatient and outpatient settings. My experiences range from bedside nursing, ambulatory care, ICU care, charge nurse, nurse manager, nurse navigator and RN coordinator. Currently, I am working as Dr. Arshad’s RN coordinator. I have been working specifically with GI cancers for the past seven years. I spearheaded and achieved NAPRC accreditation status at the University of Arizona Cancer Center. I have specialized in Bone Marrow Transplant, pain management, palliative care, wound care and end-of-life care. I hold a bachelor’s degree in nursing and a bachelor’s degree in naturopathy with an emphasis on wellness and cancer prevention. I am a Reiki Master with over 20 years of Reiki experience. I was selected as a “Fabulous 50” nurse in 2020 and successfully passed a law establishing “National Fatigue Awareness Day” in the state of Arkansas. Dr. Gagandeep Singh Surgical Oncologist, City of Hope Phoenix Internationally renowned liver and pancreas surgeon Gagandeep “Gaugs” Singh, M.D., F.A.C.S., is Chief of Surgical Oncology and Director of Surgical Services at City of Hope® Cancer Center Phoenix. A seasoned health care leader with more than 20 years’ experience building outstanding surgical teams, Dr. Singh is excited to return to Phoenix – where he completed part of his medical training – and to City of Hope, where he spent a decade as the chief of City of Hope Duarte’s surgical oncology program. In the clinic, Dr. Singh takes a thoughtful yet forceful approach to treating cancers of the liver, pancreas and gastrointestinal systems. As a health care leader, he is passionate about empowering teams to achieve their fullest potential. He has been recognized with numerous awards and leadership positions. After beginning his faculty academic career at the Keck School of Medicine at the University of Southern California in Los Angeles, Dr. Singh was appointed director of the Liver and Pancreas Center at the John Wayne Cancer Institute in Santa Monica, California, where he also served as chair of the Cancer Committee. At City of Hope Duarte, Dr. Singh spearheaded the liver and pancreatic cancer programs and led the Division of Surgical Oncology to national recognition. He has been included on multiple lists of “America’s Top Surgeons,” “Best Doctors of America,” “Super Doctors” and “Top Doctors of America.” Dr. Singh earned his medical degree from the Mahatma Gandhi Institute of Medical Sciences in India, before training at multiple internationally renowned cancer centers, including Tata Memorial Hospital and Cancer Center in Bombay, René Descartes University in Paris and the Royal Liverpool University Hospital in the United Kingdom, as well as the Marion Bessin Liver Center at the Albert Einstein College of Medicine in New York, Maricopa Medical Center in Phoenix and the University of Iowa. A board-certified surgeon, diplomate of the American Board of Surgery and fellow of the American College of Surgeons, Dr. Singh is an internationally recognized expert in his field and a member of the National Comprehensive Cancer Network for Hepatobiliary Cancers, the group that sets the guidelines for the standard of care for hepatobiliary cancers. As a researcher, Dr. Singh has written on topics such as complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions with difficult pancreatic surgery for pancreatic cancer and advanced robotic surgery. His work on robotic surgery has been presented at the Society of Surgical Oncology, America’s Hepato-Pancreato-Biliary Association, the Society of Laparoscopic & Robotic Surgeons and other national meetings. An innovator at heart, he is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborated with engineers from the California Institute of Technology and Harvey Mudd College and has several invention disclosures and patents to his name. Dr. Singh’s translational research includes projects with molecular biologists, X-ray crystallographers, structural chemists and super-resolution scientists across the City of Hope national system . Dr. Heloisa Soares Medical Oncologist, Huntsman Cancer Institute Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79 Dr. Bassam Sonbol Medical Oncologist, Mayo Clinic Phoenix Mohamad Bassam Sonbol, M.D., is an Oncologist, with special interest in neuroendocrine tumors and gastrointestinal malignancies. In addition to his clinical activities, Dr. Sonbol is active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents that could potentially help patients with neuroendocrine and gastrointestinal cancers. Dr. Sonbol focuses on the holistic treatment for cancer patients taking into consideration their medical and social aspects that have been affected by their cancer diagnosis. Dr. Holly Thompson Nuclear Medicine & Theranostics, University of Arizona Cancer Center (UACC) My passion for medicine is defined by a tenacious desire to diagnose and treat diseases that cause human suffering. Profoundly inspired by the study of cancer, I pursued research into its biology first working at the Fred Hutchinson Cancer Center and then related innovative imaging technologies working at Vitra Bioscience, following my undergraduate degree. Driven to help address cancer and other complex diseases at a more direct and personal level, I earned my Doctor of Medicine degree from the University of Miami, followed by a Masters in Public Health. After an internship in surgery at Harvard, I completed postgraduate Radiology training at UC Davis and further subspecialized in Nuclear Medicine training at Stanford University, where I learned about neuroendocrine tumors having witnessed NETTER-1 trial participants. I had the privilege of joining a large integrated healthcare provider in Northern California where I worked to enable NET patients’ early access to 177Lu-Dotatate(Lutathera, prior to FDA approval. Subsequently I became the Nuclear Medicine physician lead for regional multidisciplinary NET tumor boards facilitating patient cases to be rigorously reviewed with an integrated, patient-centered focus. Currently, as an Associate Professor at the University of Arizona, my focus is on advancing NET patient care and research, while teaching and inspiring the next generation of Nuclear Radiologist/Oncologist. It is an honor to be invited to participate in the LACNETS outreach program. Dr. Gregory Woodhead Interventional Radiology, University of Arizona Cancer Center (UACC) Gregory Woodhead, MD, PhD, joined the interventional radiology faculty at University of Arizona, with the majority of his practice focusing on interventional oncology at the University of Arizona Cancer Center. Dr. Woodhead’s career objective is to translate devices and therapies from the development stage into clinical practice. His interest in cancer cell biology draws from his PhD research on the role of the catenin-signaling pathway in cell fate decisions for progenitor and cancer cells. As a resident and fellow at the University of Arizona, he embarked on an analysis of catheter-directed mechanical thrombectomy for the treatment of acute pulmonary embolism (PE), which is a common cause of morbidity and mortality in cancer patients. He is the PI on multiple trials and registries that seek to identify long-term differences in patients who received mechanical thrombectomy for PE in comparison to those who received only anticoagulation alone. Dr. Woodhead has published over 40 papers and frequently presents at national and international meetings. He is an integral member of multiple institutional programs and a committee member for many professional societies. He is passionate about educating and mentoring medical students, residents, and fellows. He previously served as the chair of the MD/PhD admission committee.

Join NCF for Aug2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page ABOUT Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. Download Presentation Slides >>> ABOUT MEGHAN LASZLO, MS, RD, CSO Registered Dietitian Board-Certified Specialist in Oncology Nutrition Meghan Laszlo MS, RD, CSO is an oncology dietitian at Cedars-Sinai in Los Angeles, California. For individuals outside of Cedars-Sinai, Meghan Laszlo sees patients through Nourish, a telehealth platform that accepts insurance (Aetna, BCBS, Cigna, United). Insurance for telehealth is available to those residing in Arizona, California, Colorado, Connecticut, Hawaii, Idaho, Indiana, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming! Meghan Laszlo MS, RD, CSO Phone: 424-235-5026 RESOURCES T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Join NCF for 2026 Neuroendocrine Cancer Conference Recap. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page 2026 Neuroendocrine Cancer Conference Highlights ABOUT Watch the Virtual 2026 Neuroendocrine Cancer Patient Conference , a free online event designed for individuals living with neuroendocrine cancer , as well as caregivers and families seeking trusted, expert-led information. The 2026 theme, Navigating a Changing Neuroendocrine Cancer Landscape , reflected the rapid advances in neuroendocrine cancer diagnosis, treatment options, and patient care . What the Conference Covered The conference featured expert-led education on key topics in neuroendocrine cancer care, including: Understanding your neuroendocrine tumor diagnosis Overview of treatment options , including systemic and liver-directed therapies Managing treatment side effects The role of imaging and scans in monitoring disease When and how to consider surgery and clinical trials Key insights to help you navigate complex care decisions What the Conference Featured The program brought together: 19 leading NET experts sharing practical, patient-centered insights Real patient stories offering perspective and connection Expert panel discussions on supportive care and treatment decision-making Q & A sessions where specialists answered questions from the community A fully virtual format that allows viewers to pause, rewind, and replay sessions This conference is designed to help patients and caregivers feel more informed, empowered, and confident as they navigate life with neuroendocrine cancer. If you need a primer on neuroendocrine cancer, please watch the The Basics of Neuroendocrine Cancer & Newly Diagnosed Resources playlist . RECORDING Explore the conference recordings below, featuring presentations, panel discussions, patient stories, and expert Q&A sessions covering key topics in neuroendocrine cancer diagnosis, treatment, symptom management, imaging, surgery, liver-directed therapy, PRRT, clinical trials, and supportive care. These recordings are intended to provide education and support for patients, caregivers, families, advocates, and healthcare professionals seeking to better understand the evolving neuroendocrine cancer landscape. Conference Recording Welcome & Introductions https://www.youtube.com/watch?v=7pIzC3KnCNA Understanding Neuroendocrine Cancer: What to Know About My Cancer? Dr. Udhayvir Grewal, Emory Winship Cancer Institute https://www.youtube.com/watch?v=msgIWrtYX7Q Grewal_Navigating an Understanding of Neuroendocrine Cancer .pdf Download PDF • 3.38MB Navigating Scans Dr. Delphine Chen, Fred Hutch Cancer Center https://www.youtube.com/watch?v=Y-P_gGS9Vxc Chen_Navigating Scans .pdf Download PDF • 7.18MB Patient & Caregiver Journey • Sara & Quintin Share Their Story https://www.youtube.com/watch?v=lJFOB00atsY Panel Discussion (1): Navigating Supportive Care Moderator: Dr. Daneng Li, City of Hope Panelists: Dr. Chandana Banerjee, City of Hope Shelia Lindsay, NP, UCSF Victoria Ramirez, LCSW, USC https://www.youtube.com/watch?v=liornTuYWQo Navigating Surgery Dr. Julie Hallet, Sunnybrook Health Sciences Center https://www.youtube.com/watch?v=OlLSLm9lc_I Hallet_Navigating Surgery .pdf Download PDF • 983KB Navigating Liver-Directed Therapy Dr. Michael Soulen, Penn Medicine https://www.youtube.com/watch?v=4V40tYhmyiQ Soulen_Navigating Liver Directed Therapies .pdf Download PDF • 7.88MB Introduction: Navigating Treatments https://www.youtube.com/watch?v=hvLh13wdCz8 Navigating SSAs and Chemotherapy Dr. Guillaume Pegna, Oregon Health & Science University https://www.youtube.com/watch?v=EIHPypAxYG4 Pegna_Navigating SSAs and Chemotherapy .pdf Download PDF • 1.43MB Navigating Targeted Therapies and PRRT Dr. Jennifer Chan, Dana-Farber Cancer Institute https://www.youtube.com/watch?v=mRfIlaDABy4 Chan_Navigating Targeted Therapies and PRRT .pdf Download PDF • 950KB Navigating Clinical Trials Dr. Thorvardur Halfdanarson, Mayo Clinic https://www.youtube.com/watch?v=LpOMU1UPKzI Halfdanarson_Navigating Clinical Trials .pdf Download PDF • 1.33MB Navigating Treatment Sequencing Dr. Pamela Kunz, Yale Medicine https://www.youtube.com/watch?v=-11fqsut90c Kunz_Navigating Treatment Sequencing_Kunz .pdf Download PDF • 2.68MB Navigating Treatment Side Effects Dr. Jason Starr, Mayo Clinic https://www.youtube.com/watch?v=EVkVgSQ7BxU Starr_Navigating Treatment Side Effects .pdf Download PDF • 360KB Panel Discussion (2) - Navigating Treatment Decisions Moderator: Dr. Jaydira Del Rivero, National Cancer Institute Panelists: Chandrikha Chandrasekharan, MD Anderson Cancer Center Dr. Callisia Clarke, Medical College of Wisconsin Dr. Erik Mittra, Oregon Health & Science University https://www.youtube.com/watch?v=BANZAnbSnj8 Patient Journey • Katie Shares Her Story https://www.youtube.com/watch?v=0cxkJvUje40 Q&A with Experts Panel #1 : Dr. Chandrikha Chandrasekharan, MD Anderson Cancer Center Dr. Delphine Chen, Fred Hutch Cancer Center Dr. Pamela Kunz, Yale Medicine Dr. Jaydira Del Rivero, National Cancer Institute Dr. Jason Starr, Mayo Clinic Panel #2 : Dr. Michael Soulen, Penn Medicine Dr. Thorvardur Halfdanarson, Mayo Clinic Dr. Jennifer Chan, Dana-Farber Cancer Institute Dr. Udhayvir Grewal, Emory Winship Cancer Institute https://www.youtube.com/watch?v=lj_JR_EKVFg Conference Closing https://www.youtube.com/watch?v=NZkGFxRQiNA Speaker Bios 2025 Conference The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Join NCF for Sep24. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page LACNETS is hosting an in-person NET Educational Event for patients and caregivers in Minneapolis, Minnesota on Saturday, September 21st from 1:30-5:00 PM. Join us for an afternoon of NET information, connecting and networking. This program has been uniquely designed to maximize the opportunity to engage with NET specialists with two Q&A sessions. LOCATION W Minneapolis - The Foshay 821 S Marquette Ave, Minneapolis, MN 55402 For patients attending the LACNETS in-person NET Educational Event on Saturday, September 21st at the W Minneapolis – The Foshay, parking is available on-site. Please park with valet upon arrival and visit the registration desk to receive your parking validation ticket. At the time of departure, simply hand your validation ticket to the valet for complimentary parking. AGENDA Time Topic Speaker 1:30 - 2 PM Registration 2 - 2:10 PM Welcome LACNETS Team 2:10 - 2:55 PM Patient Panel with 4 NET patients Moderated by Lisa Yen, Patient Advocate & Caregiver, LACNETS 2:55 - 3:45 PM Q&A with NET Experts Chandrikha Chandrasekharan, MBBS, Medical Oncologist, University of Iowa Philip Boudreaux, MD, FACS, Surgical Oncologist, Louisiana State University 3:45 - 4 PM Break 4 - 4:20 PM Overview of Treatments Emil Lou, MD, Medical Oncologist, University of Minnesota 4:20 - 4:40 PM Sequencing of Treatments Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 4:40 - 5 PM Q&A with a NET Expert Panel Emil Lou, MD, Medical Oncologist, University of Minnesota Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic Patrick McGarrah, MD, Medical Oncologist, Mayo Clinic Ajay Prakash, MD, Medical Oncologist, University of Minnesota Donna D'souza, MD, Interventional Oncologist, University of Minnesota Philip Boudreaux, MD, Surgeon, Louisiana State University Moderated by Lisa Yen, Patient Advocate & Caregiver, LACNETS The North American Neuroendocrine Tumor Society (NANETS) is hosting their Regional NET Education Event for medical providers. Help raise awareness and knowledge of neuroendocrine cancer in the medical community by telling your local healthcare professionals to attend the NANETS Regional NET Education Event on Saturday, September 21st. This event will not be broadcast or recorded. If you are newly diagnosed, or need a refresher on NET terms and basics, we encourage you to watch Dr. Chandrasekharan’s presentation “Understanding NET Diagnosis” from our 2024 LACNETS Patient Conference . SPEAKERS: Chandrikha Chandrasekharan, MBBS Medical Oncologist, University of Iowa Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at University of Iowa. She did her initial medical training in India at Kilpauk Medical College. She moved to the USA to complete her internal medicine residency at University of Florida College of Medicine at Jacksonville. Dr. Chandrasekharan is board certified in Medical Oncology and Palliative Medicine. After completing medical oncology fellowship at LSU Shreveport, she pursued an additional year of advanced oncology training in gastrointestinal malignancies at Mayo Clinic. Dr. Chandrasekharan's clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. Thorvardur R. Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson currently serves as President for the North American Neuroendocrine Tumor Society (NANETS). Emil Lou, MD, PhD, FACP Medical Oncology, University of Minnesota Emil Lou, MD, PhD, FACP, is a medical oncologist and neuro-oncologist who provides adult patients with cancer care and treatment through chemotherapy, targeted therapy, and other tailored treatments. In addition to expertise in neuroendocrine tumors, he also specializes in helping patients with gastrointestinal cancers, paraneoplastic disorders, and solid tumor metastases to the brain. He sees patients at the University of Minnesota's Masonic Cancer Clinic at the main campus in Minneapolis. Dr. Lou is also a Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota Medical School. J. Philip Boudreaux, MD, FACS Surgical Oncologist, Louisiana State University J. Philip Boudreaux, MD, FACS, has been recognized for his outstanding contributions to the medical field. He is currently the Professor of Surgery at Louisiana State University Health Sciences Center School of Medicine in New Orleans, LA. Dr. Boudreaux educates medical students and provides high-quality care to patients. While he has held that role for over 20 years, he has spent the last 38 years expanding his knowledge and skills in liver, pancreas, kidney transplantation, organ donation, hepatobiliary and pancreatic surgery, radio frequency ablation of liver tumors, neuroendocrine tumors and carcinoids. His most recent new treatment for metastatic hepatic tumors includes Histotripsy, the destruction of tumor non-invasively with ultrasound. Dr. Boudreaux instituted the liver and pancreas transplant programs at LSU, performed the first pancreas transplant in Louisiana, and initiated the liver and kidney transplant programs at Children’s Hospital, New Orleans. He served as the Director of Liver/Pancreas/Kidney Transplant Services at LSU and Children’s Hospital pre-Katrina. Dr. Boudreaux has spoken publicly at a variety of conferences and educated residents regarding transplant and other related topics. He has published over 75 peer-reviewed publications. Dr. Boudreaux has operated upon over 2,000 patients with neuroendocrine tumors. His center continues to innovate, do research, and often finds ways to turn “inoperable” into “opportunity”. His patients enjoy some of the highest long term survival rates reported in the world’s literature to date. The NOLANETS program has expanded to include East Jefferson Hospital in partnership with the Louisiana Children’s Hospital Medical Network hospitals and the Joe Yenni Cancer Center. In his free time, Dr. Boudreaux enjoys sailing, playing music, fishing, hunting, amateur radio (call sign W5AY), and teaching. He has been a member of the Military Auxiliary Radio System (MARS) since 1968. He attributes his achievements to his education and his work ethic instilled by his parents and mentors. Patrick McGarrah, M.D. Medical Oncologist, Mayo Clinic Dr. Patrick W. McGarrah is a medical oncologist in Rochester, Minnesota and is affiliated with Mayo Clinic-Rochester. Dr. McGarrah specializes in head and neck, neuroendocrine, and gastrointestinal cancers. He received his medical degree from University of Minnesota Medical School and completed his training in 2023. Dr. McGarrah has expertise in treating neuroendocrine tumors, with special interest in poorly differentiated neuroendocrine carcinoma and NETs of the head and neck. Ajay Prakash, MD, PhD Medical Oncologist, University of Minnesota Dr. Ajay Prakash is a medical oncologist specializing in gastrointestinal malignancies. His research is focused on understanding the relationship between the tumor microenvironment, prognosis, and treatment response, with a specific focus on the role of the microbiome in this process. A better understanding of the microbiome, the community of organisms that reside in most human tissues, may allow us to better tailor treatments and offer patient specific guidance on cancer prevention. Clinically, Dr. Prakash is committed to healthcare equity and the delivery of high-quality, academic medicine to historically underserved communities. Donna D'souza, MD Interventional Radiologist, University of Minnesota Donna D’Souza MD, FSIR is an Associate Professor of Radiology and Interventional Radiologist at theUniversity of Minnesota, as well as the Interventional Radiology Medical Student Clerkship Director at the University of Minnesota. Her clinical interests are interventional oncology (especially treating cancers in the liver), portal hypertension interventions, thyroid interventions and women’s health. Dr D’Souza was born and raised in Australia. She completed her medical school at Monash University, and her Radiology Residency and Master of Medicine degree at University of Melbourne in Australia. She subsequently completed a Vascular and Interventional Radiology fellowship at the University of Toronto, followed by Interventional Radiology and Body Radiology fellowships at the University of Minnesota. In her free time she enjoys travelling the world with her husband, hiking, yoga, learning and speaking Japanese, indoor gardening, and spending time with her two dogs. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. REGISTER

THE LACNETS PODCAST Special Episode: The LACNETS Story ABOUT THIS EPISODE: In this special episode, we share the history of LACNETS – the who, what, and when. We journey down memory lane with eight special guests from before the birth of LACNETS to where it is today. This episode is dedicated to Giovanna Joyce Imbesi, the LACNETS Founder, whose vision and dedication inspires us all. Listen now! Do you have a special memory of Giovanna and LACNETS? Share your story with us here. Photo Reel: LACNETS Over the Years Storytellers THANKS TO OUR SPONSORS

Join NCF for Mar2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Pz4s1iMzBbI Some Topics Covered: Neuroendocrine, NET, NEC, High grade Clinical trials, PRRT, RLT, Antibody Drug Conjugate (ADC), DLL3 Download slides from this presentation >>> ABOUT Learn from a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. In this session, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explores novel, innovative targeted treatments used or being studied in NETs, such as DLL3 and antibody–drug conjugates (ADCs). Dr. Thummalapalli will explain what these therapies are, how they work, and why they are becoming increasingly important in NET care. Whether you’re newly diagnosed or considering later-line treatments, this webinar will help you better understand the evolving landscape of targeted therapy and what it may mean for your care. ABOUT DR. ROHIT THUMMALAPALLI Gastrointestinal Medical Oncologist Assistant Attending Physician Memorial Sloan Kettering Cancer Center Rohit Thummalapalli is a gastrointestinal medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center specializing in clinical care and research in patients with neuroendocrine and biliary tract cancers. Originally from Florida, Dr. Thummalapalli completed medical training at Harvard and Johns Hopkins before arriving at MSK as a medical oncology fellow in 2021, and started on faculty in 2024, where he focuses on caring for patients with high grade NETs and poorly differentiated NECs. RESOURCES Explore NCF's Clinical Trials Guide "NEN Treatments: Focus on DLL3" - Podcast with Dr. Rohit Thummalapalli THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Research / Clinical Trials < Back to Topics Latest News on Clinical Trials Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Play Video Play Video 03:51 Update: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors Load More Educational Videos on Research / Clinical Trials Educational Content on Research/Clinical... Play Video Play Video 19:25 11. Navigating Clinical Trials • Dr. Thorvardur Halfdanarson, Mayo Clinic • 2026 NCF Conference In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Thor Halfdanarson, medical oncologist at Mayo Clinic in Rochester, Minnesota, presents “Navigating Clinical Trials.” Dr. Halfdanarson explains why clinical trials are essential for advancing cancer care and how they help determine whether new treatments, diagnostic tools, procedures, or supportive care approaches are safe and effective. He discusses why trial participation remains low, what barriers patients may face, and why it is always worth asking whether a clinical trial may be appropriate. This presentation covers the basics of clinical trials, including eligibility criteria, trial sponsors, principal investigators, prevention trials, screening trials, diagnostic trials, treatment trials, and the differences between phase 1, phase 2, and phase 3 studies. Dr. Halfdanarson also explains randomized trials, control arms, crossover designs, clinical trial endpoints, median survival, and practical questions patients can ask when considering whether a trial is right for them. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #ClinicalTrials #CancerResearch #CancerTreatment #MayoClinic #ThorHalfdanarson #PatientAdvocacy #CancerEducation #NCF #PatientConference Play Video Play Video 01:29:26 The Latest in Neuroendocrine Cancer Clinical Trials • 2026 NCF Event • Feb 20, 2026 Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation focuses on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources. Visit the event page at https://www.ncf.net/events/feb2026 Play Video Play Video 27:02 9. The Future of NETs: Emerging Therapies & Clinical Trials • Dr. Aman Chauhan •2025 NET Cancer Day Dr. Aman Chauhan speaks about "The Future of NETs: Emerging Therapies & Clinical Trials" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 18:44 1. Demystifying Clinical Trials • Taymeyah Al-Toubah • 2025 NET Cancer Day Symposium Taymeyah Al-Toubah speaks on "Demystifying Clinical Trials" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 14:04 15. What Matters About Clinical Trials • Pamela Kunz, MD • @NCFCancer "What Matters About Clinical Trials" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Pamela Kunz, MD Medical Oncologist Yale Medicine @NCFCancer Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 33:12 "The Future of NETs: Evolving Treatments & Clinical Trials" • Jaydira Del Rivero, MD • 2024 "The Future of NETs: Evolving Treatments & Clinical Trials" with Jaydira Del Rivero, MD, Medical Oncologist/Endocrinologist, National Cancer Institute/National Institutes Of Health at the 2024 NET Cancer Day Symposium. Play Video Play Video 15:17 "The Latest in NET Medical Therapies" • Andrew Hendifar, MD, Cedars Sinai • 2024 NET Cancer Day Andrew Hendifar, MD, Medical Oncologist, Cedars Sinai, talks about the latest in NET medical therapies at the 2024 NET Cancer Day Symposium. Play Video Play Video 16:36 10. Clinical Trials: The Latest & Greatest • Pamela Kunz, MD • @NCFCancer Load More In Depth Look at Active Clinical Trials In Depth Look: Active Clinical Trials Play Video Play Video 19:41 DAREON®-NEC-1: Obrixtamig Plus Chemotherapy vs Standard Chemotherapy in Advanced epNEC • Dr. Grewal In this video, Udhayvir Grewal, MD, a gastrointestinal and neuroendocrine medical oncologist at Winship Cancer Institute of Emory University, explains the DAREON™-NEC1 clinical trial for patients with advanced DLL3-positive extrapulmonary neuroendocrine carcinoma. Dr. Grewal reviews key concepts including tumor differentiation, DLL3 testing, and how the investigational treatment obrixtamig is being studied in combination with standard chemotherapy. He also explains who may be eligible for the trial, what randomization means, what participation may involve, and important side effects to discuss with the clinical trial team, including cytokine release syndrome and ICANS. This video is intended to help patients and caregivers better understand the purpose of the DAREON-NEC1 trial, possible benefits and risks, and questions to ask when considering clinical trial participation. This content is for educational purposes only and does not constitute medical advice. Please discuss all questions, treatment decisions, and clinical trial options with your healthcare team. Learn more about clinical trials and patient resources at NCF.net. Play Video Play Video 06:46 (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET • ClinicalTrials.gov ID: NCT06943755 Dr. Aman Chauhan discusses (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors. Visit https://www.ncf.net/clinical-trials for more information. Play Video Play Video 14:15 Tarlatamab in DLL3-Expressing Tumors Including NEN • ClinicalTrials.gov: NCT06788938 • Dr. Goldman Join Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this talk, Dr. Goldman explains: - What DLL3 is and why it is an important target found on many neuroendocrine tumors - How tarlatumab works by connecting T-cells to tumor cells to trigger a focused immune response - Why DLL3-positive tumors—including small cell lung cancer, lung carcinoids, thymic tumors, pancreatic NETs, gastrointestinal NETs, prostate NEC, Merkel cell carcinoma, and others—may respond to this therapy - The structure of the L10 Clinical Trial, now in Stage 2 and enrolling across all University of California cancer centers - What patients can expect from the tarlatumab treatment schedule and dosing - Potential side effects such as cytokine release syndrome, fatigue, constipation, loss of taste, neurologic symptoms, and tumor lysis syndrome Dr. Goldman highlights both the promise of DLL3-targeted therapies and the ongoing need to understand how DLL3 expression levels relate to patient response. For more information, visit https://www.ncf.net/clinical-trials-1/tarlatamab Play Video Play Video 13:57 A Study of ZL-1310 in Participants With Selected Solid Tumors • ClinicalTrials.gov ID: NCT06885281 Dr. Rohit Thummalapalli discusses "A Study of ZL-1310 in Participants With Selected Solid Tumors" (ClinicalTrials.gov ID: NCT06885281). For more information, visit NCF.net/clinical-trials Play Video Play Video 06:54 (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen•NCT07087054 Dr. Aman Chauhan discusses (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (ClinicalTrials.gov: NCT07087054). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 08:57 Study of 225Ac-ABD147 to Establish Optimal Dose • ClinicalTrials.gov: NCT06736418 • Dr. Chauhan Dr. Aman Chauhan discusses the Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy (ClinicalTrials.gov: NCT06736418). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 12:34 May 19, 2025: Dr. Aman Chauhan discusses the DAREON-5 & DAREON-7 Studies DAREON-5 is a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. This is a clinical trial for high grade neuroendocrine cancers. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. The study is sponsored by Boehringer Ingelheim. For more information, visit https://www.lacnets.org/clinical-trials-1/dareontm--5%3A-dll-3-bite-for-neuroendocrine-cancers. Play Video Play Video 16:57 SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated NEC or Well-Differentiated High-Grade NET Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors. Recorded: April 22, 2025 For more information, visit https://www.ncf.net/clinical-trials-1/svv-001 Play Video Play Video 29:35 IL13Rα2 CAR T Cell Study for Solid Tumor Cancers • Dr. Anusha Kalbasi Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024. For more information about this trial, visit https://www.lacnets.org/clinical-trials-1/il13r%CE%B12-car-t-cell-study-for-solid-tumor-cancers. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Load More Patient Stories: Clinical Trials Patient Stories: Clinical Trials Play Video Play Video 04:08 Patient Story: NET Patient shares about her experience in a clinical trial (LACNETS) NET Patient Mary shares about her experience in a clinical trial (Everolimus or Afinitor). November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 21:23 NET Clinical Trial: An Oral Somatostatin Analogue in Patients with Carcinoid Syndrome - Jan 2024 Crinetics is sponsoring a clinical trial to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment, an oral (pill) somatostatin analogue in patients with carcinoid syndrome. Learn more about the trial and inclusion criteria here. This trial is currently open at Hoag Cancer Center in Newport Beach, California with Dr. Michael Demeure. If interested, contact Clinical Research Nurse Coordinator Jericho Rabago via direct line 949-764-6796 or email Jericho.Rabago@hoag.org. Learn about more clinical trials here: lacnets.org/clinical-trials Play Video Play Video 07:10 Patient Story: NET Patient shares her experience with Alpha PRRT NET Patient DeAnne shares her experience with Alpha PRRT. March 16th, 2021 To learn more about the LACNETS , visit www.LACNETS.org. < Back to Topics Next Topic >